QALYs Under Fire
The QALY gives a one-size-fits-all measure of value that doesn’t reflect the needs and experiences of real patients.
ICER Videos
If you don’t know ICER, you should. IfPA’s new videos explain what the health economic organization is leaving out of its analysis – and why it matters. What’s Wrong With ICER? Sometimes economists can have more control than your doctor about whether you get the medicine that treats your condition. Why Health Care Providers Should […]
ICER and the Real World
ICER recently released an updated draft of its framework. What do these changes mean for real patients who want to access innovative medicine?
Can ICER Fix What’s Broken?
It’s that time again. The controversial Institute for Clinical and Economic Review is examining its value framework, the rules and assumptions it uses to analyze new drugs’ cost effectiveness.
Rx Cost Debate Overlooks Patient Access Issues
Widespread debate erupted several weeks ago when a pharmaceutical start-up bought and raised the price of a 60-year-old drug by 5,000 percent.
Will New Value Assessments Lead to Care Rationing?
For patients, the immense value of a life-changing medication can be difficult to quantify.
